U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Mifepristone (Mifeprex)
  1. Postmarket Drug Safety Information for Patients and Providers

Mifepristone (Mifeprex)

The documents linked from this page have been redacted for certain information that is exempt from disclosure under the Freedom of Information Act, 5 U.S.C. sec. 552. This includes, for example, trade secret information, confidential commercial information, predecisional/deliberative-process information, and personal privacy information. Some of the information, such as certain government employees' names and the names of certain private citizens, is the type of information that would not ordinarily be redacted from FDA records. However, because of the particular facts and circumstances in the mifepristone approval, the agency has determined that release of certain information may pose a risk of danger to the lives or physical safety of individuals. Therefore, as permitted under the Freedom of Information Act, FDA has redacted this information under the appropriate exemption.

The full text of any published materials within this document collection, including newspaper and journal articles, has not been posted to this website because such material is copyright protected. To facilitate users' access to this information without infringing the Copyright Act, cites for such documents have been provided in the index. A list of such documents included in this collection is also posted separately.

All PDF files are available in the FDA Archive


Back to Top